The global Soft Tissue Allografts market is projected to reach $19.58 billion by 2030, growing at a CAGR of 43.51%
In 2019, the global soft tissue allografts market was worth USD 4,263.9 million, with a CAGR of 7.2 percent predicted over the forecast period. Major players in the soft tissue allografts industry have begun to recognize the prospects that is expected to boost demand for soft tissue allograft over the forecast period. Present developments in the soft tissue allografts industry, on the other hand, provide new prospects for insurance companies. The cost of an allograft operation is high as compared to autografts or synthetic leather allografts, according to our research, which is due to the limited supply of allografts. Although tissue banks can help bridge the gap and ultimately lower the cost, insurance firms can cover the cost of the operation, which can be a big win for soft tissue allografts players. As a result, it would significantly reduce the financial burden on patients, thus anticipated to fuel market growth further over the forecast period.
The global soft tissue allografts market is categorized based on type, application, and end-user. Region wise, North America was the largest market in 2019; however, Asia Pacific is expected to be the fastest growing region by 2028, with a CAGR of over 7%. The growth is attributed to rising aging population coupled with growing investment in potential emerging economies across the Asia Pacific region.
Key players serving the global soft tissue allografts market include AbbVie inc. (Allergan), Conmed Corporation, Xtant Medical Holdings Inc., Bone Bank Allografts, Smith & Nephew(Osiris Therapeutics Inc.), Stryker Corporation, Integra LifeSciences Corporation, Arthrex Inc., Zimmer Biomet, Direct Biologics among other prominent players.
Soft Tissue Allografts Market Scope
Metrics | Details |
Base Year | 2023 |
Historic Data | 2018-2022 |
Forecast Period | 2024-2030 |
Study Period | 2018-2030 |
Forecast Unit | Value (USD) |
Revenue forecast in 2030 | $19.58 billion |
Growth Rate | CAGR of 43.51 % during 2020-2030 |
Segment Covered | Type Overview,Application,End-User,Regional. |
Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
Key Players Profiled | AbbVie inc. (Allergan), Conmed Corporation, Xtant Medical Holdings Inc., Bone Bank Allografts, Smith & Nephew(Osiris Therapeutics Inc.), Stryker Corporation, Integra LifeSciences Corporation, Arthrex Inc., Zimmer Biomet, Direct Biologics among other prominent players. |
Key segments of the global soft tissue allografts market
Type Overview, (USD Million)
- Cartilage Allograft
- Tendon Allograft
- Meniscus Allograft
- Dental Allograft
- Other Types
Application Overview, (USD Million)
- Orthopedic
- Dentistry
- Wound Care
- Other Applications
End-User Overview, (USD Million)
- Hospitals
- Aesthetic Centres
- Orthopedic Clinics
- Dental Clinics
- Other End Users
Regional Overview, (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- South America
- Brazil
- Mexico
- Rest of South America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East and Africa
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global Soft Tissue Allografts industry
- The overall segmentation of soft tissue allografts market, especially key segments are thoroughly studied.
- Presence of major players and their wide product portfolio across developed countries is anticipated to further boost the growth of soft tissue allografts market
What does the report include?
- The study on the global soft tissue allografts market includes analysis of qualitative market indicators such as drivers, restraints, challenges, and opportunities
- Additionally, the market competition has been evaluated using the Porter’s five forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of applications, product, technology, and end user. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the considered segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global soft tissue allografts market is suitable for all the players across the value chain including raw material suppliers, Soft Tissue Allografts providers, pharmaceutical and medical device manufacturers, distributors, suppliers, and retailers
- Venture capitalists and investors looking for more information on the future outlook of the global soft tissue allografts market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global soft tissue allografts market
Frequently Asked Questions (FAQ) :
Soft tissue allografts are the key substitute tissue for reconstructing of deficient ligaments, osteochondral defects, and torn menisci at the time of surgery of knees. Furthermore, massive demand for allografts for the purpose of soft tissue reconstruction is due to need for stable knee helping in offering protection against more damage to ligaments & restoring of knee functions. Additionally, allografts provide myriad benefits as compared to autografts in musculoskeletal reconstructions like anterior cruciate ligament reconstruction.
Furthermore, soft tissue allografts provide better graft availability and reduction in the rate of morbidity in Orthopedic reconstructive methods. Apparently, these Application have proved to be valuable modes of treatment for patients having many kinds of injuries. For instance, these Application are useful for athletes suffering from muscular-skeletal sports injuries and patients inflicted with severe burn injuries. The product has also found application in healthcare sector where patient need solid organ transplantation.
The market for soft tissue allografts has been divided into three categories: form, application, and end-user. In the coming years, rising demand for soft tissue allografts in various sports events is expected to contribute significantly to the overall market size. Aside from that, the product's widespread use in orthopedic surgeries and oral implants will propel the soft tissue allografts industry forward in the coming years. Furthermore, an increase in the ageing population, which is vulnerable to knee or ligament disorders, as well as osteoarthritis, would characterize product demand, resulting in protuberant growth for the soft tissue allograft industry. In the years ahead, it appears that the industry's relentless emphasis on producing user-friendly products with additional functionality at competitive prices, as well as the efficient implementation of various positioning strategies, would engineer market progression. With an increase in road accidents and injuries sustained during sports events, the soft tissue allografts industry is expected to develop in the coming years.
North America is expected to be the leading market in 2021, accounting for about 33% of total market sales, while developing countries such as Brazil, India, & China are expected to expand rapidly over the forecast period from 2021 to 2028. Over the projected timeframe, demand for soft tissue allografts is expected to rise due to an ageing population and an increase in the number of trauma cases. In 2021, U.S. is anticipated to be the leading nation in the North American region. Due to the presence of major players with a strong presence, the U.S. is projected to hold the largest revenue share over the forecast period. In the United States, favorable reimbursement policies for orthopedic, cardiovascular, and other tissue reconstruction procedures are driving regional development further.
The fastest-growing regional market is expected to be Asia Pacific. Due to rising medical tourism, rising per capita income, rising government healthcare spending, and rising awareness, this area is expected to experience tremendous growth. China is expected to be the Asia Pacific region's fastest-growing economy. Between 2021 and 2028, Europe soft tissue allografts market is expected to follow the Asia Pacific market with a CAGR of ~6 percent. In Europe, growth is expected to be driven by a growing patient pool coupled with favorable healthcare policies, and a large distribution network.